PROK | ProKidney Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.3805 - 2.5200
52 Week Range	1.1200 - 13.51
Beta	2.65
Implied Volatility	583.95%
IV Rank	63.00%
Day's Volume	696,726
Average Volume	828,581
Shares Outstanding	283,119,665
Market Cap	693,643,179
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-06-30

Valuation
Profitability
Growth
Health
P/E Ratio	-4.30
Forward P/E Ratio	N/A
EPS	-0.57
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	163
Country	USA
Website	PROK

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

PROK's peers: RLAY, STOK, PLRX, BDTX, ARVN, ACLX, VTYX, IMCR, PCVX, DICE, THRD, PMVP, EWTX, ENOB, RVMD, KURA, PTGX, MRUS, REPL, CERE, GLUE, ERAS, LYEL

*Chart delayed

Analyzing fundamentals for PROK we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see PROK Fundamentals page.

Watching at PROK technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on PROK Technicals page.